1. Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment.
    L E Anselmino et al, 2021, Sci Rep CrossRef
  2. A GLUT1 Inhibitor-Based Fluorogenic Probe for Warburg Effect-Targeted Drug Screening and Diagnostic Imaging of Hyperglycolytic Cancers
    Shunjie Zhang et al, 2021, Analytica Chimica Acta CrossRef
  3. Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
    Dey Nandini et al, 2021, Pharmaceuticals CrossRef
  4. NIR Fluorescent Imaging and Photodynamic Therapy with a Novel Theranostic Phospholipid Probe for Triple-Negative Breast Cancer Cells
    Natalia I. Rubtsova et al, 2021, Bioconjugate Chem. CrossRef
  5. Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs.
    Qitong Wu et al, 2021, Cancers (Basel) CrossRef
  6. An updated review of the role of lncRNAs and their contribution in various molecular subtypes of breast cancer
    Narges Dastmalchi et al, 2021, Expert Review of Molecular Diagnostics CrossRef
  7. Ribosome Proteins Represented by RPL27A Mark the Development and Metastasis of Triple-Negative Breast Cancer in Mouse and Human
    Weipeng Zhao et al, 2021, Front. Cell Dev. Biol. CrossRef
  8. PRMT1 Confers Resistance to Olaparib via Modulating MYC Signaling in Triple-Negative Breast Cancer
    Wen-Jing Hsu et al, 2021, JPM CrossRef
  9. Obesity Modulates the Gut Microbiome in Triple-Negative Breast Cancer
    Fokhrul Hossain et al, 2021, Nutrients CrossRef
  10. Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells
    Nayanendu Saha et al, 2022, Translational Oncology CrossRef
  11. Epigenetic therapy combination of UNC0638 and CI-994 suppresses breast cancer via epigenetic remodeling of BIRC5 and GADD45A
    Hung-Yu Lin et al, 2022, Biomedicine & Pharmacotherapy CrossRef
  12. Natural inspired piperine-based ureas and amides as novel antitumor agents towards breast cancer
    Diaaeldin M. Elimam et al, 2022, Journal of Enzyme Inhibition and Medicinal Chemistry CrossRef
  13. Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models
    Enrica Balza et al, 2022, Cancer Medicine CrossRef
  14. Down-Regulation of miR-194-5p for Predicting Metastasis in Breast Cancer Cells
    Yu-Ting Yen et al, 2021, IJMS CrossRef
  15. Breast Cancer Treatment: The Case of Gold(I)-Based Compounds as a Promising Class of Bioactive Molecules
    Rossana Galassi et al, 2022, Biomolecules CrossRef
  16. Inhibition of Microtubule Dynamics in Cancer Cells by Indole-Modified Latonduine Derivatives and Their Metal Complexes
    Christopher Wittmann et al, 2022, Inorg. Chem. CrossRef
  17. Role of histone demethylases and histone methyltransferases in triple-negative breast cancer: Epigenetic mnemonics
    Janice Jacson Mandumpala et al, 2022, Life Sciences CrossRef
  18. Applications of Extracellular Vesicles in Triple-Negative Breast Cancer
    Frederic St-Denis-Bissonnette et al, 2022, Cancers CrossRef
  19. FNTB Promoter Polymorphisms Are Independent Predictors of Survival in Patients with Triple Negative Breast Cancer
    Hagen Sjard Bachmann et al, 2022, Cancers CrossRef
  20. Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature.
    Ian Landry et al, 2022, Cureus CrossRef
  21. Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers?
    Marta Marqués et al, 2022, Cancers CrossRef
  22. Low-risk triple-negative breast cancers: clinico-pathological and molecular features
    Nicola Fusco et al, 2022, Critical Reviews in Oncology/Hematology CrossRef
  23. Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes Among Taiwanese Breast Cancers
    Chi-Cheng Huang et al, 2022, Ann Surg Oncol CrossRef
  24. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy
    Ruoning Yang et al, 2022, Mol Biomed CrossRef
  25. Selective Photo-Assisted Eradication of Triple-Negative Breast Cancer Cells through Aptamer Decoration of Doped Conjugated Polymer Nanoparticles
    Luis Exequiel Ibarra et al, 2022, Pharmaceutics CrossRef
  26. Prognostic Factors and Models for Elderly (≥70 Years Old) Primary Operable Triple-Negative Breast Cancer: Analysis From the National Cancer Database
    Zhuowei Tang et al, 2022, Front. Endocrinol. CrossRef
  27. The Value of Shear Wave Elastography in the Diagnosis of Breast Cancer Axillary Lymph Node Metastasis and Its Correlation With Molecular Classification of Breast Masses
    Changyun Luo et al, 2022, Front. Oncol. CrossRef
  28. Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer
    Juan Carlos Montero et al, 2022, J Exp Clin Cancer Res CrossRef
  29. Repurposing Drugs as Novel Triple-negative Breast Cancer Therapeutics
    Amiya Das et al, 2022, ACAMC CrossRef
  30. Cinobufacini Injection Inhibits the Proliferation of Triple-Negative Breast Cancer Through the Pin1–TAZ Signaling Pathway
    Lu Kong et al, 2022, Front. Pharmacol. CrossRef
  31. The top 100 most cited articles on triple-negative breast cancer: a bibliometric analysis
    Yuyan Huang et al, 2022, Clin Exp Med CrossRef
  32. Caspase-3 mediated switch therapy of self-triggered and long-acting prodrugs for metastatic TNBC
    Ha Rin Kim et al, 2022, Journal of Controlled Release CrossRef
  33. Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC)
    Aiswarya Chaudhuri et al, 2022, Pharmaceuticals CrossRef
  34. PD-L1 expression in Congolese women with triplenegative breast cancer
    Olivier Mukuku et al, 2022, JCPCR CrossRef
  35. Discovery of novel chloropyramine-cinnamic acid hybrids as potential FAK inhibitors for intervention of metastatic triple-negative breast cancer
    Fei Yang et al, 2022, Bioorganic & Medicinal Chemistry CrossRef
  36. Emerging drug targets for triple-negative breast cancer: A guided tour of the preclinical landscape
    Xuemei Xie et al, 2022, Expert Opinion on Therapeutic Targets CrossRef
  37. Prediction of Treatment Response in Triple Negative Breast Cancer From Whole Slide Images
    Peter Naylor et al, 2022, Front. Signal Process. CrossRef
  38. Ceritinib is a novel triple negative breast cancer therapeutic agent
    Shengli Dong et al, 2022, Mol Cancer CrossRef
  39. Discovery of novel acridine-chalcone hybrids with potent DNA binding and antiproliferative activity against MDA-MB-231 and MCF-7 cells
    Mária Vilková et al, 2022, Med Chem Res CrossRef
  40. Surgical Efficacy and Prognosis of 54 Cases of Spinal Metastases from Breast Cancer
    Yao Weitao et al, 2022, World Neurosurgery CrossRef
  41. Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression
    Hsin-Yi Chen et al, 2022, J Hematol Oncol CrossRef
  42. Cost–effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer
    Min Huang et al, 2022, Immunotherapy CrossRef
  43. Coactosin-Like Protein in Breast Carcinoma: Friend or Foe?
    Bei Wang et al, 2022, JIR CrossRef
  44. The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer
    S. Michaleas et al, 2022, ESMO Open CrossRef
  45. Association of Pathway Mutations With Survival in Taiwanese Breast Cancers
    Po-Sheng Yang et al, 2022, Front. Oncol. CrossRef
  46. Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis
    Huilin Yang et al, 2022, Molecular Therapy CrossRef
  47. Silencing of COL3A1 represses proliferation, migration, invasion, and immune escape of triple negative breast cancer cells via down-regulating PD-L1 expression.
    Fan Yang et al, 2022, Cell Biol Int CrossRef
  48. Extracellular vesicles derived from Wharton’s Jelly mesenchymal stem cells inhibit the tumor environment via the miR-125b/HIF1α signaling pathway
    Yun-Hsuan Chang et al, 2022, Sci Rep CrossRef
  49. Interleukin-3-Receptor-α in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target
    Malvina Koni et al, 2022, Cancers CrossRef
  50. LLL12B, a Novel Small-Molecule STAT3 Inhibitor, Induces Apoptosis and Suppresses Cell Migration and Tumor Growth in Triple-Negative Breast Cancer Cells
    Li Pan et al, 2022, Biomedicines CrossRef
  51. Identification of necroptosis-related subtypes and prognosis model in triple negative breast cancer
    Shengyu Pu et al, 2022, Front. Immunol. CrossRef
  52. Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities
    Rita Ribeiro et al, 2022, Front. Mol. Biosci. CrossRef
  53. Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?
    Marek Z. Wojtukiewicz et al, 2022, Cancer Metastasis Rev CrossRef
  54. Annexin A2 (AnxA2) association with the clinicopathological data in different breast cancer subtypes: A possible role for AnxA2 in tumor heterogeneity and cancer progression
    Esraa Magdy Abdelraouf et al, 2022, Life Sciences CrossRef
  55. 99mTc-labeled iRGD for single-positron emission computed tomography imaging of triple-negative breast cancer
    Buhui Yu et al, 2022, Front. Bioeng. Biotechnol. CrossRef
  56. The Present and Future of Clinical Management in Metastatic Breast Cancer
    Pauline H. Lin et al, 2022, JCM CrossRef
  57. Isobavachalcone Induces Multiple Cell Death in Human Triple-Negative Breast Cancer MDA-MB-231 Cells
    Cheng-Zhu Wu et al, 2022, Molecules CrossRef
  58. Platelet-Derived Extracellular Vesicles Stimulate Migration through Partial Remodelling of the Ca2+ Handling Machinery in MDA-MB-231 Breast Cancer Cells
    Mauro Vismara et al, 2022, Cells CrossRef
  59. A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming
    Hassan Yousefi et al, 2022, Oncogene CrossRef
  60. Integrated tumor genomic and immune microenvironment analysis identifies predictive biomarkers associated with the efficacy of neoadjuvant therapy for triple‐negative breast cancer
    Yanhui Zhu et al, 2022, Cancer Medicine CrossRef
  61. Identification of immune-related signature for the prognosis and benefit of immunotherapy in triple-negative breast cancer
    Xiaorui Sun et al, 2022, Front. Genet. CrossRef
  62. Exosomal EphA2 promotes tumor metastasis of triple-negative breast cancer by damaging endothelial barrier
    Xin Liu et al, 2022, Clin Exp Metastasis CrossRef
  63. Tumor-Derived Exosomes and Their Role in Breast Cancer Metastasis
    Shaojuan Huang et al, 2022, IJMS CrossRef
  64. Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer
    Eva Kudelova et al, 2022, IJMS CrossRef
  65. FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair
    Shu-Ping Wang et al, 2021, Cell Death Dis CrossRef
  66. Enhanced Therapeutic Effect of Optimized Melittin-dKLA, a Peptide Agent Targeting M2-like Tumor-Associated Macrophages in Triple-Negative Breast Cancer
    Soyoung Kim et al, 2022, IJMS CrossRef
  67. Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical prospects
    Avinash Khadela et al, 2022, Med Oncol CrossRef
  68. A Novel Prognostic Prediction Model Based on Pyroptosis-Related Clusters for Breast Cancer
    Baoxing Tian et al, 2022, JPM CrossRef
  69. Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review
    Boya Lu et al, 2023, Technol Cancer Res Treat CrossRef
  70. HDAC7 inhibits cell proliferation via NudCD1/GGH axis in triple‑negative breast cancer
    Mengdi Zhu et al, 2022, Oncol Lett CrossRef
  71. Highly Metastatic Subpopulation of TNBC Cells Has Limited Iron Metabolism and Is a Target of Iron Chelators
    Yuze Wang et al, 2023, Cancers CrossRef
  72. 10-Gingerol Enhances the Effect of Taxol in Triple-Negative Breast Cancer via Targeting ADRB2 Signaling
    Yuqi Liang et al, 2023, DDDT CrossRef
  73. CRISPR/Cas genome editing in triple negative breast cancer: Current situation and future directions
    Leilei Fu et al, 2023, Biochemical Pharmacology CrossRef
  74. Design, synthesis and evaluation of nitric oxide releasing derivatives of 2,4-diaminopyrimidine as novel FAK inhibitors for intervention of metastatic triple-negative breast cancer
    Jinlin Zhang et al, 2023, European Journal of Medicinal Chemistry CrossRef
  75. Dysfunction of the ST7-AS1/miR-301b-3p/BTG1 ceRNA network promotes immune escape of triple-negative breast cancer
    Yong Li et al, 2023, International Immunopharmacology CrossRef
  76. A novel conditional survival nomogram for monitoring real-time prognosis of non-metastatic triple-negative breast cancer
    Xiangdi Meng et al, 2023, Front. Endocrinol. CrossRef
  77. Carbosilane ruthenium metallodendrimer as alternative anti-cancer drug carrier in triple negative breast cancer mouse model: a preliminary study
    Sylwia Michlewska et al, 2023, International Journal of Pharmaceutics CrossRef
  78. Eugenol modulates the NOD1-NF-κB signaling pathway via targeting NF-κB protein in triple-negative breast cancer cells
    Xiaoyu Shi et al, 2023, Front. Endocrinol. CrossRef
  79. Artificial intelligence: opportunities and challenges in the clinical applications of triple-negative breast cancer
    Jiamin Guo et al, 2023, Br J Cancer CrossRef
  80. Opposite and dynamic regulation of the interferon response in metastatic and non-metastatic breast cancer
    Apsana Lamsal et al, 2023, Cell Commun Signal CrossRef
  81. Anti-tumor potential and mode of action of karanjin against breast cancer; an in-silico approach
    Prarambh S R Dwivedi et al, 2023, Arabian Journal of Chemistry CrossRef
  82. MALAT-1: Immunomodulatory lncRNA hampering the innate and the adaptive immune arms in triple negative breast cancer
    Radwa Y. Mekky et al, 2023, Translational Oncology CrossRef
  83. Fluorouracil exacerbates alpha-crystallin B chain—mediated cell migration in triple-negative breast cancer cell lines
    Lili Yang et al, 2023, Sci Rep CrossRef
  84. Icariin Induces Triple-Negative Breast Cancer Cell Apoptosis and Suppresses Invasion by Inhibiting the JNK/c-Jun Signaling Pathway
    Shenghan Gao et al, 2023, DDDT CrossRef
  85. Based on immune checkpoint inhibitor to improve cancer treatment
    Yijin Chen, 2023, HSET CrossRef
  86. The Effect of Berberine Follow by Blue Light Irradiation and Valproic Acid on the Growth Inhibition of MDA-MB-231 Breast Cancer Cells
    Mahdieh Meschi et al, 2023, Appl Biochem Biotechnol CrossRef
  87. Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer
    Tomomi Sanomachi et al, 2023, Front. Oncol. CrossRef
  88. The Metabolic Landscape of Breast Cancer and Its Therapeutic Implications
    Zhuoya Jiao et al, 2023, Mol Diagn Ther CrossRef
  89. The Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy and the Epithelial–Mesenchymal Transition
    Stefano Zapperi et al, 2023, IJMS CrossRef
  90. DNAJB4 promotes triple-negative breast cancer cell apoptosis via activation of the Hippo signaling pathway
    Fang Fang et al, 2023, Discov Onc CrossRef
  91. In silico de novo drug design of a therapeutic peptide inhibitor against UBE2C in breast cancer
    Andrea Mae Añonuevo et al, 2023, J. Bioinform. Comput. Biol. CrossRef
  92. Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: an in silico experiment
    Reza Mehdizadeh et al, 2023, Sci Rep CrossRef
  93. Inhibition of VEGF binding to neuropilin-2 enhances chemosensitivity and inhibits metastasis in triple-negative breast cancer
    Zhiwen Xu et al, 2023, Sci. Transl. Med. CrossRef
  94. KK-LC-1 as a therapeutic target to eliminate ALDH+ stem cells in triple negative breast cancer
    Jiawen Bu et al, 2023, Nat Commun CrossRef
  95. Antiproliferative effects of 13α/β-steroids on triple-negative MDA-MB-231 breast cancer cells: unraveling intracellular signaling without ERα
    Alexander M. Scherbakov et al, 2023, Braz. J. Pharm. Sci. CrossRef
  96. Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology
    Aiswarya Chaudhuri et al, 2023, Cancers CrossRef
  97. A Carrier-Free Nanomedicine Enables Apoptosis-Ferroptosis Synergistic Breast Cancer Therapy by Targeting Subcellular Organelles
    Jiaxin Zhu et al, 2023, ACS Appl. Mater. Interfaces CrossRef
  98. Efficacy and Safety of Third-Line Apatinib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer Patients: A Multicenter, Retrospective, Cohort Study
    Wei Fan et al, 2023, Tohoku J. Exp. Med. CrossRef
  99. Real-world outcomes in metastatic HR+/HER2-, HER2+ and triple negative breast cancer after start of first-line therapy
    Richard W DeClue et al, 2023, Future Oncology CrossRef
  100. Nonmonotone invasion landscape by noise-aware control of metastasis activator levels
    Yiming Wan et al, 2023, Nat Chem Biol CrossRef
  101. Establishment of a novel cytokine-related 8-gene signature for distinguishing and predicting the prognosis of triple-negative breast cancer
    Xiaojun Liu et al, 2023, Front. Med. CrossRef
  102. NFYA promotes malignant behavior of triple-negative breast cancer in mice through the regulation of lipid metabolism
    Nobuhiro Okada et al, 2023, Commun Biol CrossRef
  103. Drug Target Identification in Triple Negative Breast Cancer Stem Cell Pathways: A Computational Study of Gene Regulatory Pathways Using Boolean Networks
    Aditya Lahiri et al, 2023, IEEE Access CrossRef
  104. Simultaneous Delivery of Doxorubicin and EZH2‐Targeting siRNA by Vortex Magnetic Nanorods Synergistically Improved Anti‐Tumor Efficacy in Triple‐Negative Breast Cancer
    Yunshu Lu et al, 2023, Small CrossRef
  105. A specific RAGE-binding peptide inhibits triple negative breast cancer growth through blocking of Erk1/2/NF-κB pathway
    Xiaoyong Dai et al, 2023, European Journal of Pharmacology CrossRef
  106. Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens
    Nityanand Srivastava et al, 2023, Front. Oncol. CrossRef
  107. Aptamer-grafted, cell membrane-coated dendrimer loaded with doxorubicin as a targeted nanosystem against epithelial cellular adhesion molecule (EpCAM) for triple negative breast cancer therapy
    Afsana Sheikh et al, 2023, Journal of Drug Delivery Science and Technology CrossRef
  108. Future trends in advanced triple negative breast cancer
    Javier Blanco Ávila et al, 2023, Rev Cancer CrossRef
  109. Navigating the Blood–Brain Barrier: Challenges and Therapeutic Strategies in Breast Cancer Brain Metastases
    Lucas E. L. Terceiro et al, 2023, IJMS CrossRef
  110. Targeting nuclear hormone receptors for the prevention of breast cancer
    Cassandra L. Moyer et al, 2023, Front. Med. CrossRef
  111. Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer
    Lakshmi Kumari et al, 2023, Journal of Drug Targeting CrossRef
  112. (R)-9bMS Inhibited the Protein Synthesis and Autophagy of Triple Negative Breast Cancer Cells via Regulating miR-4660/mTOR Axis
    Xiangdong Bai et al, 2023, PPL CrossRef
  113. Inhibited Expression of NLRP12 Promotes the Development of Triple-Negative Breast Cancer by Activating the NF-κB Pathway
    Wenbin Kuang et al, 2023, Cell Biochem Biophys CrossRef
  114. The calcium channel TRPC6 promotes chemotherapy-induced persistence by regulating integrin α6 mRNA splicing
    Dimpi Mukhopadhyay et al, 2023, Cell Reports CrossRef
  115. Advances in Tumour-Infiltrating Lymphocytes for Triple-Negative Breast Cancer Management
    Rok Gorenšek et al, 2023, BCTT CrossRef
  116. Immobilized doxorubicin and ribociclib carbamate linkers encaged in surface modified cubosomes spatially target tumor reductive environment to enhance antitumor efficacy
    Madhu Sharma et al, 2023, Biomaterials Advances CrossRef
  117. Role of Fisetin in Selected Malignant Neoplasms in Women
    Anna Markowska et al, 2023, Nutrients CrossRef
  118. PCMT1 knockdown attenuates malignant properties by globally regulating transcriptome profiles in triple-negative breast cancer cells
    Aili Saiding et al, 2023 CrossRef
  119. Using anti‐PD‐L1 antibody conjugated gold nanoshelled poly (Lactic‐co‐glycolic acid) nanocapsules loaded with doxorubicin: A theranostic agent for ultrasound imaging and photothermal/chemo combination therapy of triple negative breast cancer
    Hui Jiang et al, 2023, J Biomedical Materials Res CrossRef
  120. Ferroptosis induction via targeting metabolic alterations in triple-negative breast cancer
    Yaru Wang et al, 2023, Biomedicine & Pharmacotherapy CrossRef
  121. Contralateral axillary lymph node metastasis in breast cancer: An oligometastatic-like disease
    Qian Zhao et al, 2023, The Breast CrossRef
  122. Leveraging hypoxia in triple-negative breast cancer as a promising treatment strategy
    Ketki Bhise et al, 2023, Drug Discovery Today CrossRef
  123. MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer
    Zinab O. Doha et al, 2023, Nat Commun CrossRef
  124. The Combination of Radiation with PARP Inhibition Enhances Senescence and Sensitivity to the Senolytic, Navitoclax, in Triple Negative Breast Tumor Cells
    Abrar Softah et al, 2023, Biomedicines CrossRef
  125. Demethylase FTO inhibits the occurrence and development of triple-negative breast cancer by blocking m<sup>6</sup>A-dependent miR-17-5p maturation-induced ZBTB4 depletion
    Jingyi Ni et al, 2023, ABBS CrossRef
  126. Long non-coding RNA MIDEAS-AS1 inhibits growth and metastasis of triple-negative breast cancer via transcriptionally activating NCALD
    Dan Luo et al, 2023, Breast Cancer Res CrossRef
  127. Investigation of LGALS2 expression in the TCGA database reveals its clinical relevance in breast cancer immunotherapy and drug resistance
    Song He et al, 2023, Sci Rep CrossRef
  128. Drug Resistance Mechanism of Tri-ple-Negative Breast Cancer and Research Progress with DLG5
    旭升 王, 2023, ACM CrossRef
  129. TNFRSF19 promotes endoplasmic reticulum stress-induced paraptosis via the activation of the MAPK pathway in triple-negative breast cancer cells
    Shiyang Liu et al, 2023, Cancer Gene Ther CrossRef
  130. Non-Response of Epstein–Barr Virus-Associated Breast Cancer after Primary Chemotherapy: Report of Two Cases
    Ewgenija Gutjahr et al, 2023, Pathogens CrossRef
  131. miR-877-5p as a Potential Link between Triple-Negative Breast Cancer Development and Metabolic Syndrome
    Juana Moro et al, 2023, IJMS CrossRef
  132. Compartmental Syndecan-1 (CD138) expression as a Novel Prognostic Marker in Triple-Negative Metaplastic Breast Cancer
    Yahia Ismail et al, 2023, Pathology - Research and Practice CrossRef
  133. Multifunctional nanoparticles inhibit tumor and tumor-associated macrophages for triple-negative breast cancer therapy
    Yan Liu et al, 2023, Journal of Colloid and Interface Science CrossRef
  134. Breast Cancer Treatment: To tARget or Not? That Is the Question
    Alexandra Stone et al, 2023, Cancers CrossRef
  135. Low Hospital Volume Is Associated with Higher All-Cause Mortality in Black Women with Triple Negative Breast Cancer
    Samilia Obeng-Gyasi et al, 2023, J. Racial and Ethnic Health Disparities CrossRef
  136. Glutathione and acid dual-responsive nanomaterials loaded with methotrexate and magnolol for triple-negative breast cancer treatment
    Hongyi Wang et al, 2024, Materials Technology CrossRef
  137. M6A demethylase ALKBH5 regulates FOXO1 mRNA stability and chemoresistance in triple-negative breast cancer
    Xi Liu et al, 2023, Redox Biology CrossRef
  138. Transcriptome reprogramming through alternative splicing triggered by apigenin drives cell death in triple-negative breast cancer
    Meenakshi Sudhakaran et al, 2023, Cell Death Dis CrossRef
  139. Self‐Promoted Targeting Delivery of Nanodrug Through Chemotherapeutic Upregulation of CD47 for Triple Negative Breast Cancer Therapy
    Qianqian Liu et al, 2023, Adv Funct Materials CrossRef
  140. Development of Integrated Bioorthogonal Self-Catalyzed NO Donor/Platinum(IV) Prodrugs for Synergistical Intervention against Triple-Negative Breast Cancer
    Chen Zhang et al, 2023, J. Med. Chem. CrossRef
  141. A Multifunctional Liposome for Synergistic Chemotherapy with Ferroptosis Activation of Triple-Negative Breast Cancer
    Jingjing Chai et al, 2023, Mol. Pharmaceutics CrossRef
  142. The Programmed Cell Death Ligand 1 and Lipocalin 2 Expressions in Primary Breast Cancer and Their Associations with Molecular Subtypes and Prognostic Factors
    Suheyla Ekemen et al, 2024, BCTT CrossRef
  143. Circular RNA-mediated miRNA sponge & RNA binding protein in biological modulation of breast cancer
    Jing Zhu et al, 2024, Non-coding RNA Research CrossRef
  144. null
    Ouissam Al Jarroudi et al, 2023 CrossRef
  145. Recent Advances in Pyrimidine-Based Drugs
    Baskar Nammalwar et al, 2024, Pharmaceuticals CrossRef
  146. Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis
    Wei Gao et al, 2024, PLoS ONE CrossRef
  147. Efficacy and Mechanism of a Biomimetic Nanosystem Carrying Doxorubicin and an IDO Inhibitor for Treatment of Advanced Triple-Negative Breast Cancer
    Chuling Hu et al, 2024, IJN CrossRef
  148. Current Management of Brain Metastases in Breast Cancer
    Erkan Güler et al, 2024, Indian J Surg CrossRef
  149. Tumor therapy by targeting extracellular hydroxyapatite using novel drugs: A paradigm shift
    Mohammed N. Tantawy et al, 2024, Cancer Medicine CrossRef
  150. Binary prodrug nanoassemblies combining chemotherapy and ferroptosis activation for efficient triple-negative breast cancer therapy
    Lin Li et al, 2024, Chinese Chemical Letters CrossRef
  151. A Comparative Evaluation of TRPS1 and GATA3 in adenoid cystic, secretory, and acinic cell carcinomas of the breast and salivary gland
    Alireza Salem et al, 2024, Human Pathology CrossRef
  152. Imaging Molecular Targets and Metabolic Pathways in Breast Cancer for Improved Clinical Management: Current Practice and Future Perspectives
    Honest Ndlovu et al, 2024, IJMS CrossRef
  153. Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer
    Yan Liang et al, 2024, Front. Pharmacol. CrossRef
  154. NT5DC2 knockdown suppresses progression, glycolysis, and neuropathic pain in triple‐negative breast cancer by blocking the EGFR pathway
    Rui Sang et al, 2024, Molecular Carcinogenesis CrossRef
  155. Unleashing Breast Cancer Progression: miR-455-5p's Targeting of SOCS3 Drives Proliferation, Migration, and Invasion
    Xin Li et al, 2023, PPL CrossRef
  156. Evolutionary Profil of Triple-Negative Breast Cancer and Influence of Histopronostic Factors: Experience of Oncology Department Chu Ibn Rochd Casablanca
    Zineb Kabala et al, 2023, EJMED CrossRef
  157. “Triple-Punch” Strategy Exosome-Mimetic Nanovesicles for Triple Negative Breast Cancer Therapy
    Chenhong Zhang et al, 2024, ACS Nano CrossRef
  158. Fractionation and phytochemical composition of an ethanolic extract of Ziziphus nummularia leaves: antioxidant and anticancerous properties in human triple negative breast cancer cells
    Rola Abdallah et al, 2024, Front. Pharmacol. CrossRef
  159. 7-Amino-6H-anthra[9,1-cd] Isothiazol-6-one-Casein Nanosystem for Live Cell Staining and Augmenting Therapeutic Effectiveness in Triple Negative Breast Cancer
    Sajmina Khatun et al, 2024, ACS Appl. Nano Mater. CrossRef
  160. Icariin exerts anti-tumor activity by inducing autophagy via AMPK/mTOR/ULK1 pathway in triple-negative breast cancer
    Mei Zhao et al, 2024, Cancer Cell Int CrossRef
  161. Activation of MAP Kinase Pathway by Polyisoprenylated Cysteinyl Amide Inhibitors Causes Apoptosis and Disrupts Breast Cancer Cell Invasion
    Jassy Mary S. Lazarte et al, 2024, Biomedicines CrossRef
  162. Advancing immunotherapy in triple negative breast Cancer: A novel multimodal theranostic nanoplatform integrating synergetic ferroptosis and photothermal therapy
    Long Cheng et al, 2024, Chemical Engineering Journal CrossRef
  163. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
    Aditya Bardia et al, 2024, JCO CrossRef
  164. Primary adipocytes as targetable drug depot to prevent post-surgical cancer recurrence
    Yang Bo et al, 2024, Materials Today Bio CrossRef
  165. STK32C modulates doxorubicin resistance in triple-negative breast cancer cells via glycolysis regulation
    Huawei Xiao et al, 2024, Mol Cell Biochem CrossRef
  166. Identification and validation of neutrophils-related subtypes and prognosis model in triple negative breast cancer
    Shanqi Li et al, 2024, J Cancer Res Clin Oncol CrossRef
  167. Inhibition of NF-κB-Mediated Proinflammatory Transcription by Ru(II) Complexes of Anti-Angiogenic Ligands in Triple-Negative Breast Cancer
    Ayan Chakraborty et al, 2024, J. Med. Chem. CrossRef
  168. Influence of tumor microenvironment on the different breast cancer subtypes and applied therapies
    Cristina Ferreira Almeida et al, 2024, Biochemical Pharmacology CrossRef
  169. PGRN inhibits CD8+T cell recruitment and promotes breast cancer progression by up-regulating ICAM-1 on TAM
    Ting Zhou et al, 2024, Cancer Immunol Immunother CrossRef
  170. Paper-Based screen-printed electrode to detect miRNA-652-5p associated to Triple-Negative Breast Cancer
    Ada Raucci et al, 2024, Electrochimica Acta CrossRef
  171. Tumor Cell-Associated IL-1α Affects Breast Cancer Progression and Metastasis in Mice through Manipulation of the Tumor Immune Microenvironment
    Mathumathi Krishnamohan et al, 2024, IJMS CrossRef
  172. YTHDC1‐dependent m6A modification modulated FOXM1 promotes glycolysis and tumor progression through CENPA in triple‐negative breast cancer
    Xi Shen et al, 2024, Cancer Science CrossRef
  173. Heat shock factor 1 inhibition enhances the effects of modulated electro hyperthermia in a triple negative breast cancer mouse model
    Pedro H. L. Viana et al, 2024, Sci Rep CrossRef
  174. Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis
    Zhilin Liu et al, 2024, BMC Cancer CrossRef
  175. Targeting Pivotal Hallmarks of Cancer for Enhanced Therapeutic Strategies in Triple-Negative Breast Cancer Treatment—In Vitro, In Vivo and Clinical Trials Literature Review
    Anna Szulc et al, 2024, Cancers CrossRef
  176. EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer
    Ann M. Chan et al, 2024, Cancers CrossRef
  177. MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative Breast Cancer
    Si Min Zheng et al, 2024 CrossRef
  178. Regulating tumor innervation by nanodrugs potentiates cancer immunochemotherapy and relieve chemotherapy-induced neuropathic pain
    Shuting Zuo et al, 2024, Biomaterials CrossRef
  179. A Comprehensive Review on the State of the Art of Breast Cancers in Italy
    Domenico Iacopetta et al, 2024, CMC CrossRef
  180. Cancer cell membrane cloaked fluorescent liposomes loaded with metal-phenolic complex nanoparticles for combinatorial therapy against breast cancer
    Paloma Patra et al, 2024, Applied Materials Today CrossRef
  181. Exogenous Metabolic Modulators Improve Response to Carboplatin in Triple-Negative Breast Cancer
    Alyssa N. Ho et al, 2024, Cells CrossRef
  182. Chlorin Conjugates in Photodynamic Chemotherapy for Triple-Negative Breast Cancer
    Meden F. Isaac-Lam, 2024, Pharmaceuticals CrossRef
  183. Fertility Preservation in BRCA1/2 Germline Mutation Carriers: An Overview
    Erica Silvestris et al, 2024, Life CrossRef
  184. Carbon nanotubes conjugated with cisplatin activate different apoptosis signaling pathways in 2D and 3D-spheroid triple-negative breast cancer cell cultures: a comparative study
    Madalina Andreea Badea et al, 2024, Arch Toxicol CrossRef
  185. The prognostic marker KRT81 is involved in suppressing CD8 + T cells and predicts immunotherapy response for triple-negative breast cancer
    Zhideng Yan et al, 2024, Cancer Biology & Therapy CrossRef
  186. Obesity-associated metabolic inflammation promotes triple-negative breast cancer progression through the interleukin-6/STAT3/pentraxin 3/matrix metalloproteinase 7 axis
    Hailun Xie et al, 2024, International Immunopharmacology CrossRef
  187. Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies
    Nating Xiong et al, 2024, Front. Oncol. CrossRef
  188. null
    Alireza Bagheri et al, 2024 CrossRef